Akero Thinks It Will Produce A Next-Wave Therapy For NASH With Former Amgen Compound

Akero is entering the NASH race with a mechanism it thinks will be more powerful than current Phase III candidates and offer better efficacy than two other FGF-targeted candidates now in Phase II.